Your browser doesn't support javascript.
loading
Novel cell-based therapies in inflammatory bowel diseases: the established concept, promising results.
Hossein-Khannazer, Nikoo; Torabi, Shukoofeh; Hosseinzadeh, Ramin; Shahrokh, Shabnam; Asadzadeh Aghdaei, Hamid; Memarnejadian, Arash; Kadri, Nadir; Vosough, Massoud.
Affiliation
  • Hossein-Khannazer N; Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Torabi S; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
  • Hosseinzadeh R; Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Shahrokh S; Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Asadzadeh Aghdaei H; Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Memarnejadian A; Sernova Corp, London, ON, Canada.
  • Kadri N; Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden. nadir.kadri@ki.se.
  • Vosough M; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. masvos@Royaninstitute.org.
Hum Cell ; 34(5): 1289-1300, 2021 Sep.
Article in En | MEDLINE | ID: mdl-34057700
ABSTRACT
Inflammatory bowel diseases (IBDs) are chronic and relapsing disorders that affect the quality of life in many individuals around the world. Over the past few years, the prevalence of IBDs is substantially rising which might pose a considerable social and economic burden on health systems. Progresses in the management of chronic inflammatory diseases lead to prolonged remission phase and decreased hospitalization rate. However, during treatment, many patients become refractory to conventional therapies. Recently, advanced approaches using somatic cell therapy medicinal products (SCTMPs) including immune and stem cell-based therapies have drawn many researchers' attentions. Promising results from recent trials, alongside with the emerging market indicated that these therapeutic approaches could be an alternative and promising treatment to conventional therapies. In this review, we will discuss recent advances in cell-based therapies, which have been developed for treatment of IBDs. In addition, the global emerging market and the novel products in this field are highlighted.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Cell- and Tissue-Based Therapy Type of study: Risk_factors_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Hum Cell Year: 2021 Document type: Article Affiliation country: Iran

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Cell- and Tissue-Based Therapy Type of study: Risk_factors_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Hum Cell Year: 2021 Document type: Article Affiliation country: Iran
...